AQST Aquestive Therapeutics Inc.

7.39
-0.59  -7%
Previous Close 7.98
Open 7.95
Price To Book 7.86
Market Cap 184322747
Shares 24,942,185
Volume 87,542
Short Ratio
Av. Daily Volume 114,131

SEC filingsSee all SEC filings

  1. 8-K - Current report 181227755
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163429
  3. 8-K - Current report 181163364
  4. 8-K - Current report 181146939
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181052633

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Top-line data due December 2018.
AQST-117
Amyotrophic Lateral Sclerosis
Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Sympazan
Lennox-Gastaut Syndrome
NDA filing due early 2019.
Libervant - AQST-203
Epileptic seizures
CRL issued November 16, 2018.
AQST-119
Erectile dysfunction
PDUFA date January 2019.
APL-130277
Parkinson’s Disease with motor fluctuations

Latest News

  1. Aquestive Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
  2. Aquestive Therapeutics Announces Late-Breaking Findings of its Investigational Diazepam Buccal Film (DBF) Formulation in Adults with Epilepsy
  3. Aquestive Therapeutics Launches SYMPAZAN™ (clobazam) Oral Film with Widespread U.S. Availability
  4. Market Trends Toward New Normal in Transcat, BioXcel Therapeutics, Youngevity International, Aquestive Therapeutics, TORM, and Transglobe Energy — Emerging Consolidated Expectations, Analyst Ratings
  5. The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates
  6. Aquestive Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration (FDA) for Tadalafil Oral Film
  7. Aquestive Therapeutics: 3Q Earnings Snapshot
  8. Aquestive Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights
  9. Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval for SYMPAZAN™ (clobazam) Oral Film
  10. Aquestive Therapeutics to Present at the Stifel 2018 Healthcare Conference
  11. Aquestive Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Business Highlights on November 6, 2018
  12. Aquestive Therapeutics Announces Completion of Diazepam Buccal Film Adult Epilepsy Monitoring Unit (EMU) Clinical Study with Positive Topline Results
  13. Aquestive Therapeutics Names Lori J. Braender, Esq. as Senior Vice President, General Counsel
  14. Aquestive Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights, Including Tentative Approval for Sympazan™
  15. Aquestive Therapeutics Announces Tentative FDA Approval for Sympazan™ (clobazam) Oral Film
  16. Aquestive Therapeutics Announces Closing of Exercise of Underwriters' Over-Allotment Option in Initial Public Offering
  17. Aquestive Therapeutics Names Sandy Costa as Chairman of the Board of Directors
  18. Aquestive Therapeutics to Present at the 2018 Wedbush Healthcare Conference
  19. Aquestive Therapeutics Announces Closing of Initial Public Offering

SEC Filings

  1. 8-K - Current report 181227755
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163429
  3. 8-K - Current report 181163364
  4. 8-K - Current report 181146939
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181052633
  6. 8-K - Current report 181051227
  7. 8-K - Current report 181022430
  8. 8-K - Current report 181012398
  9. S-8 - Securities to be offered to employees in employee benefit plans 18975148
  10. 8-K - Current report 18975106